tuneTypical Dose
Evidence is too inconsistent for a confident typical dose
Botanical
Moringa
Moringa oleifera
Evidence TierDWADA NOT PROHIBITED
watchEffect Window
Cardiometabolic trials are usually several weeks long.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Moringa has inconsistent cardiometabolic evidence, with current meta-analytic data not supporting dependable broad benefit.
Moringa is marketed as a superfood for blood sugar, blood pressure, and lipids, but the clinical trial record is inconsistent. A 2025 meta-analysis in Nutrients found no robust cardiometabolic benefit overall and rated certainty very low. That means moringa is still more hypothesis than dependable protocol.
Moringa has plausible antioxidant and metabolic mechanisms, but controlled human benefits remain inconsistent and low certainty.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- No dependable broad cardiometabolic benefit established
Secondary Outcomes
- Possible small and inconsistent blood-pressure effects
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
Side effects
- GI upset
Interactions
No entries provided
Avoid if
- You are using it as a substitute for evidence-based diabetes or blood-pressure care
Evidence
Study-level References
mor-SRC-001Systematic review and meta-analysis of randomized controlled trials with GRADE assessment
Sourceopen_in_newCrișan D, Gavrilaș L, Păltinean R, Frumuzachi O, Mocan A, Crișan G. Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Nutrients. 2025;17(22):3501. doi:10.3390/nu17223501. PMID:41305552.
Population: Adults from nine randomized controlled trials of moringa supplementation.
Dose protocol: Mixed moringa supplement regimens across randomized trials
Key findings: No robust benefit across most cardiometabolic outcomes.
Notes: Best current meta-analysis.
Paper content
This is the clearest current summary of moringa for cardiometabolic outcomes and it is largely negative. Across 9 RCTs with 12 study arms, pooled effects were null for most anthropometric, lipid, and glycemic endpoints. A small diastolic-blood-pressure signal appeared in the main analysis, but it did not survive sensitivity testing, and the authors graded the certainty of evidence as very low across all evaluated outcomes because of risk of bias, indirectness, and substantial heterogeneity.
mor-SRC-002Randomized controlled trial
Sourceopen_in_newKushwaha S, et al. Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy. 2023. PMID:37229639.
Population: Adults with type 2 diabetes.
Dose protocol: Daily moringa leaves in type 2 diabetes
Key findings: No clear between-group fasting-glucose benefit.
Notes: Useful direct negative trial.
Paper content
This direct trial reinforces the weak overall evidence picture for moringa. It did not show clear cardiometabolic superiority versus control.
mor-SRC-003Narrative review of 22 clinical trials and 9 case reports.
Sourceopen_in_newSianipar EA, Sumiwi SA, Susilawati Y, Levita J. Moringa oleifera Lamk. as a promising adjunct therapeutic candidate: a narrative review of human studies and published case reports. Drug Des Devel Ther. 2026;20:586556. doi:10.2147/DDDT.S586556. PMID:41710586.
Population: Diverse populations across 22 clinical trials, including individuals with HIV, prediabetes, malnutrition, and metabolic disorders.
Dose protocol: Various moringa preparations across 22 clinical trials
Key findings: Consistent improvements in immune function, glycemic control, and antioxidant status in HIV, prediabetes, and malnutrition populations. Rare hypersensitivity and thrombotic events noted.
Notes: Narrative review, not systematic. Useful for breadth of human evidence mapping.
Paper content
This narrative review compiled 22 clinical trials and 9 case reports examining moringa in human populations. It found consistent improvements in immune function, glycemic control, and antioxidant status, particularly among individuals with HIV, prediabetes, and malnutrition. The review positions moringa as a "safe and accessible functional food" and potential adjunct therapeutic candidate. However, rare hypersensitivity and thrombotic events were noted as safety signals. As a narrative rather than systematic review, it does not pool effect sizes or formally assess bias, so the conclusions should be read as qualitative synthesis rather than quantitative evidence. It is useful for mapping the breadth of human evidence and identifying subpopulations where moringa shows the most consistent signals.